



## Supplementary material

## Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE

**Table 1 of the supplementary material**

Baseline Characteristics for the Entire Population and According to All-cause Mortality

Variables	CA125 determined		P-value
	no n = 90	yes n = 422	
Age (y)	79 ± 5	79 ± 6	.861
Male sex, n (%)	47 (52)	200 (47)	.405
Logistic EuroSCORE (%)	14 [8-20]	14 [9-22]	.362
Non-TF access	45 (50)	185 (44)	.286
Self-expandable/Balloon-expandable THV, n (%)	43 (48)	173 (41)	.231
Body mass index, kg/m <sup>2</sup>	28 ± 5	27 ± 4	.028
Diabetes, n (%)	34 (38)	134 (32)	.269
Hypertension, n (%)	73 (81)	304 (72)	.076
Atrial fibrillation, n (%)	30 (33)	142 (34)	.954
Previous SAVR, n (%)	2 (2)	9 (2)	.958
Previous CABG, n (%)	9 (10)	54 (13)	.463
Previous CAD, n (%)	38 (42)	166 (39)	.612
Previous PCI, n (%)	31 (34)	109 (26)	.096
Previous malignoma, n (%)	12 (13)	65 (15)	.618
Previous MI, n (%)	9 (10)	38 (9)	.767
<sup>a</sup> Previous stroke, n (%)	7 (8)	49 (12)	.290
<sup>b</sup> Renal failure, n (%)	34 (38)	148 (35)	.626
<sup>c</sup> COPD, n (%)	12 (13)	57 (14)	.965
Peripheral arterial disease, n (%)	14 (16)	58 (14)	.654
Pacemaker, n (%)	3 (3)	40 (10)	.056
Previous dialysis, n (%)	2 (2)	20 (5)	.285
NYHA III/IV, n (%)	80 (89)	352 (83)	.194
Creatinine (mg/dL)	1.27 ± 0.90	1.38 ± 1.10	.349
LVEF ≤ 35%, n (%)	10 (11)	31 (7)	.235

Maximal gradient, mmHg	73 ± 22	78 ± 25	.116
<sup>d</sup> PAH, n (%)	3 (10)	28 (7)	.233
Aortic valve area, cm <sup>2</sup>	0.72	0.71	.481

CA125, tumor marker carbohydrate antigen 125; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PCI, percutaneous coronary intervention; SAVR, surgical aortic valve replacement; TF, transfemoral; THV, transcatheter heart valve.

<sup>a</sup>Severely affecting ambulation or day-to-day functioning.

<sup>b</sup>Serum creatinine > 200 µmol/L.

<sup>c</sup>On long-term use of bronchodilators or steroids.

<sup>d</sup>Pulmonary artery pressure ≥ 60mmHg.

Unless otherwise indicated, values are presented as mean ± standard deviation or as the median [interquartile range].

**Table 2 of the supplementary material**

Reclassification Among Patients Who Experienced an Event and Those not Experiencing An Event During Follow-up

Reclassification among patients who experience an event and those not experiencing an event during follow-up			
Model without CA125	Model with CA125		
Frequency (row per cent)	0-27%	> 27%	Total
<i>Patients who experienced an event</i>			
0-27%	30	16	46
> 27%	13	56	69
Total	43	72	115
<i>Patients not experiencing an event</i>			
0-27%	185	21	206
> 27%	36	65	101
Total	221	86	307

CA125, tumor marker carbohydrate antigen 125.

**Figure of the supplementary material:** Cumulative mortality during follow-up according to the acquisition of CA125.

CA125, tumor marker carbohydrate antigen 125.

**Supplemental Figure 1 –Mortality According to available baseline CA125 measurments**

